Log in

600671 Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd SSE · China

Hangzhou Tianmushan Pharmaceutical Enterprise Co (600671) news

Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd is a public biotech or pharmaceutical company listed on SSE under the ticker 600671, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Hangzhou Tianmushan Pharmaceutical Enterprise Co news

We have not published a story on Hangzhou Tianmushan Pharmaceutical Enterprise Co yet. When there is news, it will appear here.

Questions about Hangzhou Tianmushan Pharmaceutical Enterprise Co

What is the ticker symbol of Hangzhou Tianmushan Pharmaceutical Enterprise Co?

Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd trades under the ticker 600671 on SSE.

Where is Hangzhou Tianmushan Pharmaceutical Enterprise Co listed?

Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd is listed on SSE.

Which country or territory is Hangzhou Tianmushan Pharmaceutical Enterprise Co listed under?

Our directory records Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd under China.

What does Hangzhou Tianmushan Pharmaceutical Enterprise Co do?

Our directory classifies Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Hangzhou Tianmushan Pharmaceutical Enterprise Co?

The ISIN recorded for Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd is CNE000000BF3.

Does aibio.space cover Hangzhou Tianmushan Pharmaceutical Enterprise Co?

aibio.space lists Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Hangzhou Tianmushan Pharmaceutical Enterprise Co?

Companies in our directory listed in the same country and business area as Hangzhou Tianmushan Pharmaceutical Enterprise Co: Jinling Pharmaceutical Co., Hainan Huluwa Pharmaceutical Group Co., Chimin Health Management Co., Anhui Anke Biotechnology (Group) Co., Everest Medicines, Shanghai Yizhong Pharmaceutical Co..

Investor discussion: Hangzhou Tianmushan Pharmaceutical Enterprise Co

Members talk about Hangzhou Tianmushan Pharmaceutical Enterprise Co (600671). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open SSE:600671 on TradingView.

Listing details

Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd is a public biotech or pharmaceutical company listed on SSE under the ticker 600671, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd
Ticker
600671
Listing
SSE
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
CNE000000BF3
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.